Advertisement
Advertisement

Eight heart inflammation cases among young kids who got COVID-19 shot – U.S. CDC

By:
Reuters
Updated: Dec 16, 2021, 18:08 UTC

(Reuters) -The U.S. Centers for Disease Control and Prevention said on Thursday it had received reports of eight cases of myocarditis, a type of heart inflammation, in children aged 5-11 years who received Pfizer and BioNTech's COVID-19 vaccine.

Children age 5-11 receive vaccination against the coronavirus disease (COVID-19)

(Reuters) -The U.S. Centers for Disease Control and Prevention said on Thursday it had received reports of eight cases of myocarditis, a type of heart inflammation, in children aged 5-11 years who received Pfizer and BioNTech’s COVID-19 vaccine.

The CDC had previously said that reporting rates of myocarditis for boys aged 16 to 17 could be more than 69 cases per million second doses administered and around 40 cases per million second doses in boys aged 12-15 years old.

The CDC did not say whether it believes there is a link between the myocarditis cases and the vaccine, or disclose the rate of myocarditis in the age group without vaccination.

The agency said there had been over 7 million vaccine doses in the 5-11 age group at the time it examined the data, with 5.1 million first doses and 2 million second doses. The cases had a mild clinical course, the CDC said.

The cases were reported in the U.S. Vaccine Adverse Event Reporting System and presented by the CDC to a panel of its expert advisers.

(Reporting by Manas Mishra in Bengaluru and Michael Erman in New Jersey; Editing by Shailesh Kuber)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?

Advertisement